Canaccord analyst Whitney Ijem reiterated a Buy rating and $429.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).

The analyst commented: "Last week ALNY held its first “RNAi Roundtable” of 2026 (10th series), starting with ALN-6400: Targeting Plasminogen to Address a Wide Range of Bleeding Disorders. In addition to a review of Phase 1 data, Phase 2 study design and status, and next steps, we also heard from KOLs and a patient to underscore the unmet need in both hereditary hemorrhagic telangiectasia (HHT) and Von Willebrand Disease (VBD). Looking ahead, we’re focused on the top line Phase 2 data in HHT as the next stock moving catalyst for ALNY. We currently do not include ALN-6400 in our model but do give the company early pipeline revenue credit. Maintain BUY."

For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.

Shares of Alnylam Pharmaceuticals closed at $293.52 yesterday.